A Phase 2 interventional study of OC-01 (varenicline) nasal spray and Placebo (vehicle) nasal spray in Dry Eye Disease, sponsored by Oyster Point Pharma, Inc.. Completed at 3 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2021-10-25.
Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing varenicline in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Varenicline · Dry Eye Syndromes.
Among the 13 studies testing varenicline in Dry Eye Syndromes, this one is the 3rd largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 1st registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →2 of the 13 studies testing varenicline in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:
Ocular Aesthetics, LLC dba Ocular Clinical Trials · Sites in United States
Ages 18–99 · Healthy volunteers
University of California, Berkeley · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2018.
This study's enrollment of 182 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 13 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 9 most frequent:
This study is registered under Oyster Point Pharma, Inc., one of the names counted as Viatris Inc.. Under that name alone:
Oyster Point Pharma, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Viatris Inc. has 9 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies testing varenicline in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07705893Ocular Aesthetics, LLC dba Ocular Clinical TrialsTreating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg | 2026-12 |
| NCT07606625University of California, BerkeleyOcular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing varenicline in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease
This was a Phase 2b, multicenter, randomized, double-masked, placebo controlled study designed to evaluate the safety and efficacy of OC 01 nasal spray in adult subjects with DED. The study randomized 182 subjects, at least 22 years of age, who had a physician's diagnosis of dry eye disease and met all other study eligibility criteria to receive an application of OC-01 or placebo twice daily (BID) for 4 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OC-01 (varenicline) nasal spray, Low Dose, 0.12 mg/mL
Drug: OC-01 (varenicline) nasal spray
OC-01 (varenicline) nasal spray Mid dose, 0.6 mg/mL
Drug: OC-01 (varenicline) nasal spray
OC-01 (varenicline) nasal spray High dose, 1.2 mg/mL
Drug: OC-01 (varenicline) nasal spray
Placebo (vehicle) nasal spray
Drug: Placebo (vehicle) nasal spray
OC-01 (varenicline) nasal spray
Placebo
Mean Change in Schirmer's Test Score From Baseline to 28 Days
The primary end point was the change in anesthetized Schirmer's Test Score (STS) from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test score from 0-35 mm where a higher score is indicative of a better outcome.
Time frame: 28 Days [Visit 1 (baseline) and Visit 5 (28 days)]
Change From Baseline in Eye Dryness Score From Baseline to Day 28
Change in Eye Dryness Score from baseline to 28 days. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.
Time frame: 28 days [Visit 1 (baseline and Visit 5 (28 days)]
Change From Baseline to Day 21 in Eye Dryness Score at 5 Minutes Post Treatment in the CAE.
Change from baseline to Day 21 in Eye Dryness Score at 5 minutes post treatment in the CAE. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.
Time frame: 21 days [Visit 1 (baseline) and Visit 4 (21 days)]
| Milestone | OC-01 Low Dose, 0.12 mg/ml | OC-01 Mid Dose, 0.6 mg/ml | OC-01 High Dose, 1.2 mg/ml | Placebo |
|---|---|---|---|---|
| Started | 47 | 48 | 44 | 43 |
| Completed | 47 | 46 | 40 | 43 |
| Not completed | 0 | 2 | 4 | 0 |
The primary end point was the change in anesthetized Schirmer's Test Score (STS) from baseline to 28 days in the study eye following treatment with OC-01. Schirmer's test score from 0-35 mm where a higher score is indicative of a better outcome.
| score on a scale, mm | OC-01 Low Dose, 0.12 mg/mL | OC-01 Mid Dose, 0.6 mg/ML | OC-01 High Dose, 1.2 mg/mL | Placebo |
|---|---|---|---|---|
| Mean Change in Schirmer's Test Score From Baseline to 28 Days | 10.1 ± 1.26 | 11.7 ± 1.27 | 11.0 ± 1.39 | 3.2 ± 1.31 |
Change in Eye Dryness Score from baseline to 28 days. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.
| score on a scale, mm | OC-01 Low Dose, 0.12 mg/ml | OC-01 Mid Dose, 0.6 mg/ml | OC-01 High Dose, 1.2 mg/ml | Placebo |
|---|---|---|---|---|
| Change From Baseline in Eye Dryness Score From Baseline to Day 28 | -11.6 ± 3.63 | -18.9 ± 3.67 | -15.6 ± 4.02 | -5.4 ± 3.8 |
Change from baseline to Day 21 in Eye Dryness Score at 5 minutes post treatment in the CAE. Eye Dryness (EDS) on a Visual Analogue Scale (VAS) from 0 (no discomfort) to 100 (maximum discomfort) millimeters where a lower score is indicative of a better outcome.
| score on a scale, mm | OC-01 Low Dose, 0.12 mg/ml | OC-01 Mid Dose, 0.6 mg/ml | OC-01 High Dose, 1.2 mg/ml | Placebo |
|---|---|---|---|---|
| Change From Baseline to Day 21 in Eye Dryness Score at 5 Minutes Post Treatment in the CAE. | -8.1 ± 2.7 | -16.0 ± 2.7 | -18.4 ± 3.0 | -4.4 ± 2.8 |
Collected over Adverse Events were collected from the first dose of study drug administration until the final study visit at Visit 5 (28 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OC-01 Low Dose, 0.12 mg/mL | 0/47 (0%) | 0/47 (0%) | 33/47 (70.2%) |
| OC-01 Mid Dose, 0.6 mg/mL | 0/48 (0%) | 1/48 (2.1%) | 44/48 (91.7%) |
| OC-01 High Dose, 1.2 mg/mL | 0/44 (0%) | 0/44 (0%) | 41/44 (93.2%) |
| Placebo | 0/43 (0%) | 0/43 (0%) | 11/43 (25.6%) |
| Event | OC-01 Low Dose, 0.12 mg/mL | OC-01 Mid Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/47 | 1/48 | 0/44 | 0/43 |
| Event | OC-01 Low Dose, 0.12 mg/mL | OC-01 Mid Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo |
|---|---|---|---|---|
| SneezingRespiratory, thoracic and mediastinal disorders | 29/47 | 38/48 | 37/44 | 0/43 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/47 | 6/48 | 11/44 | 0/43 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 0/47 | 7/48 | 9/44 | 0/43 |
| Instillation site irritationGeneral disorders | 3/47 | 8/48 | 8/44 | 0/43 |
| Ocular TEAEsEye disorders | 1/47 | 2/48 | 1/44 | 7/43 |
| Dysaesthesia pharynxRespiratory, thoracic and mediastinal disorders | 5/47 | 4/48 | 3/44 | 0/43 |
| Visual acuity reducedEye disorders | 1/47 | 1/48 | 0/44 | 3/43 |
| Nasal drynessRespiratory, thoracic and mediastinal disorders | 1/47 | 0/48 | 0/44 | 2/43 |
| HeadacheNervous system disorders | 0/47 | 0/48 | 2/44 | 1/43 |
| BlepharospasmEye disorders | 0/47 | 0/48 | 0/44 | 1/43 |
| Age, Continuous(years) | OC-01 Low Dose, 0.12 mg/mL | OC-01 Mid Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 64.2 ± 12.7 | 66.5 ± 9.4 | 67.4 ± 10.6 | 64 ± 10.3 | 65.5 ± 10.8 |
| Sex: Female, Male(Participants) | OC-01 Low Dose, 0.12 mg/mL | OC-01 Mid Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|---|---|
| Female | 36 | 34 | 35 | 32 | 137 |
| Male | 11 | 14 | 9 | 11 | 45 |
| Ethnicity (NIH/OMB)(Participants) | OC-01 Low Dose, 0.12 mg/mL | OC-01 Mid Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 3 | 2 | 5 | 18 |
| Not Hispanic or Latino | 39 | 45 | 42 | 38 | 164 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | OC-01 Low Dose, 0.12 mg/mL | OC-01 Mid Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 0 | 2 |
| Asian | 3 | 4 | 0 | 1 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 2 | 4 | 6 | 2 | 14 |
| White | 42 | 39 | 36 | 40 | 157 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | OC-01 Low Dose, 0.12 mg/mL | OC-01 Mid Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|---|---|
| United States | 47 | 48 | 44 | 43 | 182 |
| Schirmer's Test Score(mm) | OC-01 Low Dose, 0.12 mg/mL | OC-01 Mid Dose, 0.6 mg/mL | OC-01 High Dose, 1.2 mg/mL | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 5.2 ± 3.1 | 4.8 ± 2.7 | 5.5 ± 3.0 | 4.5 ± 2.9 | 5.0 ± 2.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Sep 2018, 1 month.
Results were first posted in Oct 2021, 3 years after primary completion. A results delay was requested in May 2019.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 1 month is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline